Bould Opportunities PLC

Equities

PSL

GB00B1TK2453

Construction Supplies & Fixtures

Delayed London S.E. Other stock markets 02:30:01 2019-10-07 am EDT			5-day change	1st Jan Change
0.023 ^GBX	-.--%		+24.32%	+43.75%

2021	Bould Opportunities plc Reports Earnings Results for the Full Year Ended December 31, 2020	CI
2021	Cizzle Biotechnology Limited completed the acquisition of Bould Opportunities PLC from Antos Glogowski and others in a reverse merger transaction.	CI

PhotonStar LED Group PLC Announces Board Changes

February 28, 2013 at 02:01 am EST

PhotonStar LED Group plc appointed Russell Banks as Group Finance Director with effect from 2 April 2013. David Holloway, the current finance director is stepping down and will leave the Group. Russell was previously Chief Financial Officer at Ark Therapeutics plc Prior to that he was Senior Director of Finance, Europe at NASDAQ listed biopharmaceutical company, Cephalon Inc, and until 1998 he was Group Financial Controller at mail order business, Compton & Woodhouse Ltd.

Latest news about Bould Opportunities PLC

Bould Opportunities plc Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-21	CI
Cizzle Biotechnology Limited completed the acquisition of Bould Opportunities PLC from Antos Glogowski and others in a reverse merger transaction.	21-05-12	CI
Bould Opportunities PLC Announces Board Changes	21-04-23	CI
Cizzle Biotechnology Limited agreed to acquire Bould Opportunities PLC from Antos Glogowski and others for £21 million in a reverse merger transaction.	21-04-22	CI
Antos Glogowski cancelled the acquisition of PhotonStar Technology Ltd. from Bould Opportunities PLC.	20-04-30	CI
Photonstar Led Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-27	CI
Bould Opportunities PLC Announces Change of Registered Office	19-09-18	CI
Bould Opportunities plc Reports Earnings Results for the Full Year Ended December 31, 2018	19-06-26	CI
Bould Opportunities PLC Announces Board Changes	19-05-21	CI
Antos Glogowski offered to acquire PhotonStar Technology Ltd. from Bould Opportunities PLC for £1.	19-04-30	CI
PhotonStar To Seek Acquisitions	19-03-06	CI
Photonstar Led Group plc Announces the Change of Registered Office Address	19-01-31	CI
PhotonStar LED Group PLC Announces Management Changes	19-01-30	CI
Paul Macleur and other members of the management team of Camtronics Vale Limited cancelled the acquisition of Camtronics Vale Limited from PhotonStar LED Group PLC in a management buyout transaction.	19-01-29	CI
PhotonStar LED Group Plc Announces Resignation of Majd Zoorob as Director	19-01-22	CI
PhotonStar LED Group PLC announced that it has received £0.1 million in funding	19-01-16	CI
PhotonStar LED Group PLC Appoints Martin Lampshire as Non-Executive Director	19-01-14	CI
Photonstar Still Considering Strategic Options For Photonstar Technology	18-11-20	CI
PhotonStar Group Considers Options For PhotonStar LED	18-10-31	CI
PhotonStar LED Group PLC Announces Partnership with Housing Association to Help Deliver the Association's Smart Estates Vision	18-10-19	CI
PhotonStar LED Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-09-28	CI
PhotonStar LED Group PLC Reports Audited Consolidated and Company Earnings Results for the Year Ended December 31, 2017	18-06-29	CI
PhotonStar LED Group PLC Releases v2 halcyon cloudBMSTM product	18-05-02	CI
PhotonStar LED Group PLC Provides Earnings Guidance for the Ended 31 December 2017	18-01-30	CI
Paul Macleur and other members of the management team of Camtronics Vale Limited entered into an agreement to acquire Camtronics Vale Limited from PhotonStar LED Group PLC in a management buyout transaction for £0.61 million.	18-01-29	CI

Chart Bould Opportunities PLC

Duration

Period

More charts

Company Profile

Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.

Sector

Construction Supplies & Fixtures

Calendar

2024-06-24 - Annual General Meeting

More about the company

Sector Lighting Fixtures

	1st Jan change	Capi.
BOULD OPPORTUNITIES PLC	+43.75%	3.54M
ACUITY BRANDS, INC.	+24.18%	7.76B
SIGNIFY N.V.	-17.55%	3.38B
OPPLE LIGHTING CO.,LTD	+10.36%	1.95B
FAGERHULT GROUP AB	+3.48%	1.15B
FW THORPE PLC	-7.69%	540M
LSI INDUSTRIES INC.	+6.25%	421M
SHANGHAI LUOMAN TECHNOLOGIES INC.	-54.45%	397M
SHENZHEN SNC OPTO ELECTRONIC CO.,LTD	-32.61%	375M
SHENZHEN REFOND OPTOELECTRONICS CO.,LTD.	-31.97%	362M

Lighting Fixtures